Advancements in Antibody-Drug Conjugates for Breast Cancer

This chapter explores the complexities of antibody-drug conjugates (ADCs) in treating metastatic BRCA-negative, triple-negative breast cancer, focusing on sequencing therapies and resistance mechanisms. The discussion also covers emerging combinations of ADCs with immune checkpoint inhibitors, targeting nuances in HER2 classification and the implications for treatment decisions.